论文部分内容阅读
测定ABO(H)血型同族抗原可预测膀胱癌,只是这种测定假阴性较多,特别是O(H)型的病人。近年来,技术的进步,例如使用单一细胞混悬液,孟买血液(Bowbay blood)免疫荧光和免疫过氧化物酶染色法等,目前已解决了上述误差问题。作者复习7年期间退伍军人中141例确诊为过渡型细胞膀胱癌的病例,分析其ABO(H)血型。大多数病人未涉及RH因子,分泌状态(Secretor States)或次要血型等问题。并随机选择同期100例非泌尿系疾病病人的血型作对照。此141例膀胱癌病人,均系男性,年龄39～92岁,平均68.5岁,其中A型血58例,O(H)型54
Determination of ABO (H) blood group antigen can predict bladder cancer, but this test false negative more, especially O (H) type of patients. In recent years, advances in technology, such as the use of single cell suspensions, Bowman’s blood immunofluorescence and immunoperoxidase staining, have now solved the above error problem. The authors reviewed 141 cases of transitional cell bladder cancer among veterans over a seven-year period and analyzed their ABO (H) blood group. Most patients do not deal with issues such as RH factor, Secretor States or secondary blood types. And randomly selected during the same period in 100 cases of non-urological diseases in patients with blood type control. The 141 cases of bladder cancer patients, all male, aged 39 to 92 years, mean 68.5 years, of which 58 cases of type A blood, O (H) type 54